Cardlytics, Inc. (NASDAQ:CDLX) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Q1 2023 Cardlytics, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode.
Cardlytics Inc. (CDLX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 88,700,000 | $38,125,072 | 0% | ||
| 2. | CAS Investment Partners Clifford A. Sosin | 5,416,116 | $18,387,714 | 3.77% | |
| 3. | 683 Capital Partners Ari Zweiman | 1,825,000 | $6,195,874 | +5% | 0.46% |
| 4. | General Equity Partners Andrew Bellas | 1,508,988 | $5,123,014 | +72% | 12.05% |
| 5. | 11,025,000 | $4,410,000 | -3% | 0.32% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.80 | 3,000 | Director | 61,798 | 2022-11-09 | Filing | |
| $3.95 | 6,000 | Director | 58,798 | 2022-11-08 | Filing | |
| $4.24 | 6,000 | Director | 52,798 | 2022-11-07 | Filing | |
| $16.92 | 2,000 | Director | 46,798 | 2022-08-15 | Filing | |
| $16.65 | 1 | Director | 44,798 | 2022-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.92 | 6 | Director | 248,779 | 2022-11-08 | Filing | |
| $3.93 | 4 | Director | 313,547 | 2022-11-08 | Filing | |
| $3.92 | 1 | Officer | 8,123 | 2022-11-08 | Filing | |
| $4.00 | 68 | Officer | 21,413 | 2022-11-08 | Filing | |
| $4.32 | 1,234 | Officer | 21,481 | 2022-11-07 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 58,112,000 | $24,980,896 | 0.26% | |
| 2. | 33,928,000 | $15,492,038 | 0.18% | |
| 3. | 2,587,138 | $8,783,334 | 0% | |
| 4. | 20,160,000 | $8,618,400 | 0.04% | |
| 5. | 1,778,502 | $6,038,014 | 0% |
News See All
Cardlytics, Inc. (NASDAQ:CDLX) Q4 2022 Earnings Call Transcript
Operator: Hello! And thank you for standing by. Welcome to the Cardlytics Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time all participants are in a listen only mode.
12 Stocks To Sell According to Motley Fool
In this article, we will be looking at 12 stocks to sell according to Motley Fool.
5 Most Volatile Stocks to Buy Now
Omnicell, Inc. (NASDAQ:OMCL) provides medication management solutions and adherence tools for healthcare systems and pharmacies in the United States and internationally.
10 Best Stocks to Buy According to Ari Zweiman’s 683 Capital Partners
In this article, we present the list of top 10 stock picks of Ari Zweiman’s 683 Capital Partners at the end of the second quarter.
Analysts Just Trimmed Their Price Targets of These 10 Stocks
In this article, we will take a look at the 10 stocks that recently received price-target cuts from analysts.
5 Stocks You Should Sell According to Motley Fool
In this article, we discuss 5 stocks you should sell according to Motley Fool.
Here's Why Headwaters Capital Sold its Cardlytics (CDLX) Stake
Headwaters Capital, an investment management firm, published its third-quarter 2021 investor letter – a copy of which can be downloaded here.
Hedge Funds Are Souring On Cardlytics, Inc. (CDLX)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter.
Is Cardlytics, Inc. (CDLX) A Good Stock To Buy?
In this article we are going to use hedge fund sentiment as a tool and determine whether Cardlytics, Inc. (NASDAQ:CDLX) is a good investment right now.
Billionaire Hedge Funds
